Jiangsu Aidea Pharmaceutical Co., Ltd.
SSE:688488.SS
14.04 (CNY) • At close June 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 417.805 | 411.364 | 244.219 | 255.71 | 289.056 | 345.225 | 276.906 | 136.264 | 257.842 |
| Cost of Revenue
| 188.291 | 245.006 | 139.446 | 170.837 | 144.262 | 197.304 | 166.306 | 95.292 | 136.065 |
| Gross Profit
| 229.513 | 166.358 | 104.773 | 84.872 | 144.794 | 147.921 | 110.6 | 40.972 | 121.778 |
| Gross Profit Ratio
| 0.549 | 0.404 | 0.429 | 0.332 | 0.501 | 0.428 | 0.399 | 0.301 | 0.472 |
| Reseach & Development Expenses
| 0 | 73.923 | 63.908 | 47.671 | 26.316 | 27.86 | 34.282 | 34.224 | 18.928 |
| General & Administrative Expenses
| 0 | 25.239 | 38.347 | 14.588 | 19.672 | 17.125 | 14.162 | 8.797 | 32.908 |
| Selling & Marketing Expenses
| 0 | 104.417 | 75.495 | 27.742 | 21.588 | 29.275 | 25.421 | 15.658 | 11.219 |
| SG&A
| 147.662 | 203.418 | 113.843 | 42.33 | 41.259 | 46.4 | 39.583 | 24.455 | 44.128 |
| Other Expenses
| 156.429 | -18.936 | 40.107 | 42.056 | 29.325 | 24.902 | -0.622 | -0.042 | 3.041 |
| Operating Expenses
| 393.979 | 258.406 | 217.858 | 132.057 | 96.9 | 99.163 | 96.974 | 81.629 | 66.413 |
| Operating Income
| -151.827 | -98.345 | -113.084 | -47.185 | 49.55 | 35.2 | 8.224 | -44.683 | 17.846 |
| Operating Income Ratio
| -0.363 | -0.239 | -0.463 | -0.185 | 0.171 | 0.102 | 0.03 | -0.328 | 0.069 |
| Total Other Income Expenses Net
| -14.171 | 6.26 | -0.311 | 1.563 | -2.366 | 2.948 | -0.686 | -0.039 | 4.26 |
| Income Before Tax
| -165.997 | -92.085 | -142.385 | -42.274 | 47.185 | 38.148 | 7.538 | -44.722 | 22.106 |
| Income Before Tax Ratio
| -0.397 | -0.224 | -0.583 | -0.165 | 0.163 | 0.111 | 0.027 | -0.328 | 0.086 |
| Income Tax Expense
| -27.162 | -16.015 | -18.182 | -12.289 | 7.413 | 4.499 | -1.08 | -6.735 | 7.869 |
| Net Income
| -129.919 | -76.07 | -124.203 | -29.986 | 39.772 | 33.649 | 8.618 | -37.987 | 14.237 |
| Net Income Ratio
| -0.311 | -0.185 | -0.509 | -0.117 | 0.138 | 0.097 | 0.031 | -0.279 | 0.055 |
| EPS
| -0.31 | -0.18 | -0.3 | -0.071 | 0.095 | 0.08 | 0.023 | -0.1 | 0.038 |
| EPS Diluted
| -0.31 | -0.18 | -0.3 | -0.071 | 0.095 | 0.08 | 0.023 | -0.1 | 0.038 |
| EBITDA
| -97.465 | -39.296 | -96.12 | -4.949 | 74.715 | 71.002 | 30.267 | -27.633 | 34.734 |
| EBITDA Ratio
| -0.233 | -0.096 | -0.394 | -0.019 | 0.258 | 0.206 | 0.109 | -0.203 | 0.135 |